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Editorial Comment
Percutaneous Balloon
Valvuloplasty: Long-Term Studies
Are Needed*
ROBERT H. BEEKMAN , MD, FACC
Ann Arbor. Michigan
The cardiac catheterization laboratory is undergoing a re-
markable transition. What was originally a diagnostic lab-
oratory is becoming a therapeutic suite where interventional
procedures may, in many cases, replace surgery altogether.
Percutaneous balloon angioplasty or valvuloplasty has been
used for several years in pediatric cardiology centers for
treatment of congenital valvular pulmonary stenosis, pul-
monary artery stenosis and recurrent postoperative coarc-
tation of the aorta; in fact, angioplasty is now the procedure
of choice for these three lesions (I). During the past 2 to 3
years balloon angioplasty has also been utilized for con-
genital valvular aortic stenosis (2,3), subaortic stenosis (4),
mitral stenosis (5,6) and native coarctation (7,8), and trans-
catheter techniques for closure of patent ductus arteriosus
and atrial septal defect (9) and ablation of accessory path-
ways (10) have been developed. In adult cardiology per-
cutaneous transluminal coronary angioplasty has become a
routine procedure. Further, balloon valvuloplasty of calcific
aortic stenosis ( I I) and rheumatic mitral stenosis has re-
cently aroused tremendous interest. At the 1986 American
Heart Association meeting in Dallas 15 abstracts were pre-
sented on these two topics alone.
Balloon mitral valvuloplasty. McKay and coworkers
(12) have made a significant contribution to our understand-
ing of balloon mitral valvuloplasty. In the current issue of
the lou mal they have carefully documented the acute, short-
term benefits of percutaneous balloon valvuloplasty for
rheumatic mitral stenosis. In 18 adult patients mitral val-
vuloplasty resulted in a 78% increase in mitral valve area,
associated with a 40% decrease in mean valve gradient and
a 19% increase in cardiac output. The procedure was not
associated with any important complications and, notably,
severe mitral regurgitation and embolic events were not
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observed. On follow-up all patients reported lessening of
their symptoms of dyspnea, orthopnea and fatigue.
McKay et al. (12) have also helped to elucidate the mech-
anisms by which balloon valvuloplasty relieves rheumatic
mitral stenosis. Balloon dilation in five postmortem hearts
relieved the mitral obstruction through separation of fused
commissural edges and fracture of calcified areas within the
leaftets. These changes are consistent with those described
in aortic valves after balloon dilation of congenital and cal-
cific aortic stenosis (2, II ), In no instance has damage to
the anulus, tearing of leaflets or liberation of calcific debris
been detected. These observations may help to explain the
apparent infrequency of severe valvular regurgitation and
embolic events after balloon mitral and aortic valvuloplasty .
Technical aspects. Comments regarding some technical
aspects of the procedure are in order. Percutaneous mitral
'Ialvuloplasty requires one or two transseptal punctures and
dilation of the puncture site to introduce the valvuloplasty
catheter or catheters into the left atrium. It is important to
recognize that the atrial septal defect that is produced could
improve hemodynamic indexes of mitral stenosis, without
any real change in mitral valve function. By decompressing
the left atrium an atrial septal defect alone would decrease
left atrial and pulmonary artery wedge pressures, decrease
the mitral valve gradient, increase the cardiac output (as
spuriously measured by thermodilution technique in the pul-
monary artery) and, thereby, increase the calculated mitral
valve area. McKay et a!. (12) correctly appreciated the
potential confounding effects of an atrial septal defect, and
noted that hemodynamic improvement was similar in pa-
tients with and without a detectable atrial shunt. Further-
more, improved mitral valve function was confirmed by
echocardiographic and radionuclide studies. Nevertheless,
it is prudent to minimize the size of the atrial septal defect
required for the procedure. This may be accomplished by
use of the double-balloon technique in which smaller val-
vuloplasty catheters are necessary than when a single cath-
eter is employed. In addition, both catheters can be intro-
duced into the left atrium through a single transseptal punc-
ture by use of a double-lumen exchange catheter (as described
by McKay et al. ), or by passing two exchange wires through
a single transseptal sheath positioned in the left atrium or
ventricle ,
Long-term studies are lacking. Although several
studies have now documented short-term effectiveness of
percutaneous balloon mitral and aortic valvuloplasty , more
data are needed before these procedures should become
routine. Long-term data are lacking, and real questions re-
main. Which patients are most likely to benefit from the
procedure? How long will gradient relief persist after bal-
loon valvuloplasty? What is the course of mitral or aortic
insufficiency after balloon valvuloplasty? Will the atrial sep-
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tal defect created during mitral valvuloplasty become he-
modynamically important if mitral stenosis recurs or left
ventricular end-diastolic pressure increase s with time ? Per-
haps most importantly, how do the result s of balloon val-
vuloplasty compare with those of surgical valvotomy? These
questions will be answered only through careful evaluation
of balloon valvuloplasty in strict clinical protocol s, ideally
in controlled clinical trials. Such studies are needed soon.
There exists a critical window in time during which proper
evaluation of a new therapy is feasible: after effecti veness
is documented , but before the new therapy is accepted as
routine medical practice. For percutaneous balloon valvu-
loplasty the time is now . Balloon mitral and aortic valvu-
loplasty are exciting new techniques but, at present, they
should be used only in the context of investigative protocols .
Such studies, and preferably controlled clinic al trials, must
be performed to determine the ultimate role of percutaneou s
balloon valvuloplasty in the treatment of children and adults
with mitral or aortic stenosis.
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